Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
Drugs|July 18, 2019
Targeting BCL2 in Chronic Lymphocytic Leukemia and Other Hematologic MalignanciesFevzi F Yalniz, William G Wierda
Transplantation and Cellular Therapy|March 30, 2026
Impact of Pre-Transplant Hypomethylating Agents on Reduced-Intensity Conditioning Allogeneic Hematopoietic Cell Transplantation in Myelodysplastic Syndrome with Good or Intermediate-Risk CytogeneticsYanal Alnimer, Ayman Qasrawi, Ashley Soule, et al.
The Journal of Molecular Diagnostics : JMD|November 30, 2024
The Validation of Digital PCR-Based Minimal Residual Disease Detection for the Common Mutations in IDH1 and IDH2 Genes in Patients with Acute Myeloid LeukemiaJing Di, Tao Sheng, Ranjana Arora, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|March 19, 2018
Steroid Refractory Chronic Graft-Versus-Host Disease: Cost-Effectiveness AnalysisFevzi F Yalniz, Mohammad H Murad, Stephanie J Lee, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|May 13, 2017
Safety and Efficacy of Infliximab Therapy in the Setting of Steroid-Refractory Acute Graft-versus-Host DiseaseFevzi F Yalniz, Mehrdad Hefazi, Kristen McCullough, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|July 6, 2020
Chimeric Antigen Receptor Therapy: How Are We Driving in Solid Tumors?Uri Greenbaum, Fevzi F Yalniz, Samer A Srour, et al.
American Journal of Hematology|October 13, 2017
Therapy related-chronic myelomonocytic leukemia (CMML): Molecular, cytogenetic, and clinical distinctions from de novo CMMLMrinal M Patnaik, Rangit Vallapureddy, Fevzi F Yalniz, et al.
European Journal of Haematology|November 13, 2024
Unveiling the Genetic and Clinical Differences of Acute Myeloid Leukemia (AML) in Obese PatientsFevzi F Yalniz, Anna Johnson, Yanal Alnimer, et al.
British Journal of Haematology|August 31, 2019
A phase II study of addition of pracinostat to a hypomethylating agent in patients with myelodysplastic syndromes who have not responded to previous hypomethylating agent therapyFevzi F Yalniz, Jesus G Berdeja, Michael B Maris, et al.
Cancer|February 27, 2020
Significance of minimal residual disease monitoring by real-time quantitative polymerase chain reaction in core binding factor acute myeloid leukemia for transplantation outcomesFevzi F Yalniz, Keyur P Patel, Qaiser Bashir, et al.
Pageof 2